Last reviewed · How we verify

NCT02911883

Evaluation of the Repeatability and Reproducibility of AngioVue

Completed Last updated 20 June 2017
What this trial tests

trial testing Optical Coherence Tomography Angiography in Normal, Glaucoma & Retinal Pathology in 70 participants. Completed in 2 February 2017.

Timeline
29 August 2016
Primary endpoint
1 February 2017
2 February 2017

Quick facts

Lead sponsorOptovue
StatusCompleted
Study typeOBSERVATIONAL
Enrollment70
Start date29 August 2016
Primary completion1 February 2017
Estimated completion2 February 2017

Drugs / interventions tested

Conditions studied

Sponsor

Optovue

Who can join

18 and older, any sex, with Normal, Glaucoma & Retinal Pathology. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the repeatability and reproducibility of measurements of the vascular structures and the anatomical structures of the posterior pole of the eye based on AngioVue volume scans in normal subjects, glaucoma patients, and retina patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Optical Coherence Tomography Angiography

Trials testing the same drug.

Other Optovue trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02911883.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing